Kynos Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10 Max Born Crescent, Edinburgh, Midloth...Phone Number
+44 1316517957Website
www.kynostx.comRevenue
$7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Kynos Therapeutics
We are a dedicated team with proven expertise and success in translational research, medicines discovery and clinical developmentExplore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kynos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kynos Therapeutics
Kynos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Kynos Therapeutics has new funding data
Check out if Kynos Therapeutics is spiking on competitors!
Product Launch: Get notified when Kynos Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Kynos Therapeutics recently announced quarterly report
Click to see if Kynos Therapeutics had a recent Job posting/layoffs
Check if Kynos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Kynos Therapeutics
Compare insights from companies similar to Kynos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Kynos Therapeutics
$7M
11-50
Private
$11.8M
-
N/A
Company Profile Activity
Activity Insights
Kynos Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kynos Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kynos Therapeutics.
Kynos Therapeutics financials insights
Gather financial insights about Kynos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Grant
$3.3M
Unspecified
$8.5M
Kynos Therapeutics Tech Stack
A closer look at the technologies used by Kynos Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Executive Move
Board of Directors
Funding
Funding
Kynos Therapeutics News & Media
Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and chronic inflammatory disorders, today announces the key findings from the first-in-human Phase I trial of its lead drug candidate, KNS366.Kynos expands senior team with Strutt as CFO - Daily Business
Kynos Therapeutics, the Scottish biotech company, has announced the appointment of Dr Alison Strutt as chief finance officerKynos Therapeutics targets inflammation-driven illness - PharmaTimes
Spin-off company will focus on developing therapies in areas of inflammation and immunometabolism - News - PharmaTimesKynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism Kynos programmes are focused on three key areas: in critical illness post-surgery; in...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kynos Therapeutics
Sign Up For FreeTo access detailed company insights
We are a dedicated team with proven expertise and success in translational research, medicines discovery and clinical development... Read More
